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No speciﬁc treatment can reverse the liver injury in cirrhosis. This study aims to characterize immune status and correlations
between cirrhosis induced by HBV and HCV. Phenotypes of peripheral blood lymphocyte subsets (T, NK, regulatory T cells) and
Th cytokine secretion were analyzed using ﬂow cytometry in 42 HBV-cirrhotic and 40 HCV-cirrhotic patients. Cirrhotic patients
had a lower proportion of CD3+CD8+T cells and NK cells, while the proportion of CD3+CD4+T cells and Treg cells were higher
than those of healthy controls. The levels of Th2 cytokine (IL-6) in cirrhotic patients were increased, while only the Th1 cytokine
(IFN-γ) increased in HBV-cirrhotic patients. These ﬁndings show that there is no diﬀerence between the cirrhotic groups except
in the IFN-γ level. In cirrhosis, defects in innate, adaptive immune cells are likely regardless of which virus is involved. A cytokine
imbalance may play a role in the development of posthepatitic cirrhosis.
1.Introduction
Cirrhosis is the twelfth leading cause of death, account-
ing for 27,000 deaths each year worldwide. It is caused
mostly by hepatitis B and C infection, alcoholism, and
autoimmune liver diseases. Hepatitis B virus is probably
the most common cause of cirrhosis in most of the world,
but in the United States and Western countries, chronic
alcoholism and hepatitis C are the most common causes
[1]. Ten to thirty percent of patients with chronic hepatitis
B develop liver cirrhosis, and up to 20% with chronic
hepatitis C develop cirrhosis [2]. Conventional treatment for
cirrhosis can stop or slow progression of the disease and
reduce complications, but it cannot reverse liver damage.
Consequently, understanding the disease process, making
appropriate risk stratiﬁcation, and implementing treatment
require a valid and precise understanding of the immune
status.
Although the pathogenesis of viral chronic liver disease
is not well understood, there is a consensus that the liver
damage is immune-mediated [3]. The importance of innate,
adaptive immune responses in combating hepatitis virus
infections and progression is poorly characterized. Most
of the studies indicate that HBV and HCV usually evade
early and late immune responses. HBV, a hepadnavirus, and
HCV, a ﬂavivirus, have distinct viral structures, replication
mechanisms,pathogenesis,andkinetics.However,theyshare
several aspects of natural history and adaptive immune
responses [4]. An infection with HCV or HBV activates the
immune system to defend the host with a broad range of
innate and adaptive immune responses. Some reports on the
immunopathogenesis of chronic HBV and HCV infection
have suggested that CD8 T cells, CD4 T cells, Treg cells, and
NK cells as well as cytokines participate in the development
of liver pathology [5].
Besides quantitative diﬀerences, qualitative changes of
the immune response may also play a crucial role in
determining the resolution or persistence of infection. To
our knowledge, little data have been reported concerning
the immune status and mechanisms of cirrhosis. Therefore,
this study focused on the proportion of peripheral blood
lymphocyte subsets and Th cytokine proﬁles in cirrhotic
patients caused by HBV and HCV infection to characterize
functional variations of the immune status and determine
the correlation between liver cirrhosis of diﬀerent causes and
their immunologic features.2 Journal of Biomedicine and Biotechnology
Table 1: Demographic characteristics and clinical features.
Characteristics HBV-Cirrhosis (n = 42) HCV-Cirrhosis (n = 40) Hepatitis B
Non-cirrhotic (n = 26)
Healthy Controls
(n = 21)
Sex 22 male (52%)‡ 20 male (50%)‡ 14 male (54%)‡ 11 male (52%)‡
Age (Years) 50 (33–77)† 55 (43–73)† 52 (26–70)† 59 (27–69)†
ALT (units/L) 54.0 (13.4–526.6)† 54.5 (12.9–191)† 72.5 (43.2–458)† <40
AST (units/L) 68.0 (22.2–458)† 57.8 (19.0–245.6)† 80.3 (44.9–487)† <40
TBIL (μmol/L) 41.9 (9.4–403.4)† 20.5 (10.1–245.6)† 44.6 (15.8–368)† <17.1
Viral loads (log10copies/ml) 4.5 (3.0–7.3)† 3.6 (3.0–5.6)† 4.2 (3.0–6.9)† NA
Child-Pugh classiﬁcation
A 12 (29%)‡ 13 (33%)‡ NA NA
B 19 (46%)‡ 16 (40%)‡ NA NA
C 11 (25%)‡ 11 (27%)‡ NA NA
Normal values: ALT, ≤40IU/L; AST, ≤40IU/L, TBIL ≤17.1μmol/l; HBV DNA and HCV RNA ≤3log 10copies/ml; † Data are expressed as median (range);
‡ Data are expressed as %.
2.MaterialsandMethods
2.1. Patients. A total of 82 cirrhotic inpatients who were
treated at the Hepatology Unit of the First Hospital of Jilin
University from February 2009 to July 2009 were prospec-
tively included in the study, and 21 healthy donors and 26
hepatitis B patients without cirrhosis served as controls. The
diagnosis of cirrhosis was made by clinical signs, including
evidence of liver decompensation, and conﬁrmed by liver
CT, ultrasound examination, serum liver tests (ALT, alanine
aminotransferase; AST, aspartate aminotransferase; TBIL,
total bilirubin; ALB, albumin; PT, prothrombin time), and
blood cell counts. In 4 cases in which the diagnosis was not
clear, cirrhosis was also conﬁrmed by liver biopsy. Twenty
patients had normal AST and ALT, and 62 had elevated AST
and ALT. The majority (75%) had serum levels of the virus
with over 103 copies per mL. Twenty-ﬁve percent of patients
had undetectable viral loads, of which 11 and 14 patients
wereHBV-andHCV-cirrhoticpatients,respectively.Twenty-
seven patients had ascites, 10 patients had encephalopathy,
and 8 patients had esophageal variceal bleeding. Among the
42 HBV-cirrhotic patients, 18 were HBeAg-positive and 24
were HBeAg-negative. Twelve of the HBV-cirrhotic patients
included in the study were taking nucleoside/nucleotide
analogantiviraltherapy.FourofthemhadundetectableHBV
DNA. Patients who received interferon treatment during the
previous year before sampling were excluded. Patients with
human immunodeﬁciency virus, other types of hepatitis,
or carcinoma were also excluded. The study protocol con-
formed to the ethical guidelines of the 1975 Declaration
of Helsinki and was approved by our institutional Review
Committee. Written informed consent was obtained from
each participant. Demographic characteristics and clinical
features of the patients are summarized in Table 1.
2.2. Virological Assessment. HBsAg, anti-HBs, anti-HBc,
HBeAg, anti-HBe, and anti-HCV were determined by
enzyme immunoassay kits (Abbott Laboratories and InTec
PRODUCTS, Inc.). Quantitation of serum HBsAg was
performed by comparing the optical densities of diﬀerent
serum sample dilutions with reference curves (Architect
quantitative HBsAg, Abbott, IL). HBV DNA and HCV RNA
levels were quantiﬁed by hybridization assay (Shenzhen PG
Biotech Co., Ltd.).
2.3. Flow Cytometry. All antibodies were from BD Bio-
sciences.
Tregs were estimated based on the previously published
m et h odo fL i ueta l .[ 6]. Each sample of isolated lymphocytes
was washed and resuspended in a staining buﬀer containing
PBS and 0.1% BSA. Two μl of ﬂuorescein-conjugated speciﬁc
antibodies was added to the lymphocytes, vortexed and
incubated on ice for 20 minutes. To the cells, 500μlo f
staining buﬀer was added and cells pelleted.
Numbers of T and NK lymphocytes were deter-
mined in anticoagulated peripheral blood according to
the manufacturer’s instructions with the following modi-
ﬁcations. To each tube containing 50μl of whole blood,
TriTEST CD4 FITC/CD8 PE/CD3 PerCP and TriTEST
CD3 FITC/CD16+CD56 PE/CD45 PerCP were added. The
samples were incubated at room temperature for 1 hour.
Following incubation, erythrocytes were lysed using 1ml
FACS lysing solution (eBioscience Inc., USA). The cells were
washed twice with 2ml PBS buﬀer [7].
Isotype-matched antibodies were used as controls for all
the samples. All the samples were analyzed using a FACSCal-
ibur instrument (BD Biosciences) and Flowjo software. At
least 20,000 events per run were acquired.
2.4. Cytokine Production. Levels of Th cytokines (IFN-γ,
TNF-α, IL-10, IL-6, IL-4, IL-2) were determined by CBA
(BD Pharmingen, USA) based on the previously published
method of Ahmed et al. [8]. The concentrations of all
six cytokines in each well were calculated using BD CBA
Software.
2.5. Statistical Analysis. All clinical and ﬂow cytometry data
were compared using the Wilcoxon rank sum test and Chi-
square test. SAS version 9.0 software was used. CorrelationsJournal of Biomedicine and Biotechnology 3
were determined using Spearman’s correlation test. Results
are given in median (range), unless speciﬁed otherwise.
3. Results
3.1. Peripheral Blood Lymphocyte Subpopulations. Alter-
ations in the peripheral lymphocyte subsets are shown
in Figures 1 and 2. There were no signiﬁcant diﬀerences
in lymphocyte subsets between the two cirrhotic groups.
However, the proportions of lymphocyte subsets were sig-
niﬁcantly diﬀerent between the cirrhotic groups and healthy
controls. The CD4/CD8 ratio and CD3+CD4+ cells were
higher, while the CD3+CD8+Foxp3+ cells and NK cells were
lower in the cirrhosis groups than in the healthy control
group. The increase in the CD4/CD8 ratio was a combined
result of a relative increase in CD3+CD4+ cells and decrease
in CD3+CD8+ cells. The proportion of CD4+CD25+ Treg
cells in patients was dramatically higher than those in
healthy controls. Analysis of lymphocyte subsets showed no
diﬀerence between the HBV-cirrhotic patients and hepatitis
B patients without cirrhosis.
3.2. Relationship of Peripheral Lymphocyte Subsets to Clinical
Parameters. Considering the diﬀerent clinical phenotypes,
cirrhotic patients were divided into groups: HBeAg positive
or negative, high or low viral load (>5l o g 10 copies/ml or <5
log10 copies/ml) high or low aminotransferases (>80 units/L
or <80 units/L), and Child-Pugh A, B, C. No correlation
was observed between the viral load, Child-Pugh score,
hepatic inﬂammation or HBeAg status, and the percentage
of peripheral lymphocyte subsets. There was no relation
between the lymphocytes and nucleoside/nucleotide analog
antiviral treatment in HBV-cirrhotic patients. A signiﬁcant
correlation was obtained between HBsAg titers and HBV
DNA levels (R = .461, P = .015).
3.3. Cytokine Production. Changes in levels of Th cytokines
are summarized in Table 2.N od i ﬀerences in Th1 or Th2
cytokine patterns were observed between cirrhotic groups,
except for IFN-γ, which was dramatically higher in HBV-
cirrhotic patients than that in HCV-cirrhotic patients (P =
.037). IL-6 concentrations were higher in cirrhotic patients
than those in controls. The IFN-γ/IL-6 ratio in cirrhotic
groups was dramatically lower than that in controls (P =
.035). However, serum TNF-α, IL-2, IL-4, and IL-10 concen-
trations did not diﬀer among these three groups.
3.4. Relationship of Cytokine Levels to Clinical Parameters and
Peripheral Lymphocyte Subsets. IL-6 levels were signiﬁcantly
diﬀerent among Child-Pugh A (n = 36), B (n = 50),
and C (n = 30) groups (P = .002). They were highest
in the C group and lowest in the A group (P = .0013).
The association between levels of IL-6 stratiﬁed by TBIL
less than twice and greater than 5-times the upper limit of
normal (34.2 and 88.5U/L, resp.) and HBsAg titer twice
the upper limit of detection (500IU/ml) among cirrhotic
patients was further analyzed. IL-6 levels in the cirrhotic
groupsweresigniﬁcantlylowerinindividualswith<34.2U/L
TBIL (n = 39) compared to those with >88.5U/L (n = 38)
(P = .012). IL-6 levels in the HBV-cirrhotic group were
signiﬁcantly higher in patients with <500IU/ml HBsAg titer
(n = 29) compared to those with >500IU/ml (n = 32)
(P = .031).
4. Discussion
Innate host responses during the early phases of viral
infections are characterized by the activation of NK cells [2].
The current study found a reduced frequency of NK cells in
post-hepatitis cirrhosis which is in agreement with previous
research indicating an inadequacy of innate host response
and ineﬃcient initiation of adaptive immune response [9,
10]. We also showed that no diﬀerence was found between
the nonviremic and viremic groups, which is inconsistent
with the results of Zarife et al. [7]. Diﬀerent methodologies,
including the CD45 labeling, smaller sample sizes, and
diﬀerences in severity of disease, might explain why some of
the ﬁndings in these studies diﬀered from ours. The decrease
of NK cells could be a hallmark of innate immunity in
cirrhotic individuals. As discussed previously, low levels of
these cells in cirrhotic patients may be due to intrahepatic
compartmentalization or induction of apoptosis of virus-
speciﬁcimmunecellsinthedevelopmentofoptimalimmune
responses [11]. However, published data do not support this
possibility.
T h ec e l l u l a ri m m u n er e s p o n s eh a sb e e ns h o w nt ob e
a major contributor to HBV and HCV clearance [12]. We
detected a shift in the CD4/CD8 ratio, due to a relative
increase in the number of CD4+T cells and decrease in
the number of CD8+T cells [13]. The observed defect in
CD8 cells is consistent with previous reports. The precise
mechanism responsible for this impaired T-cell response is
not known. One interpretation is that activation-induced
cell death results in a vast amount of T-cell deletions as
demonstrated in chronic HBV infection. Another possible
interpretation is that the high frequency of Tregs had an
immunosuppressive eﬀect on the T-cells. Previous studies
have demonstrated that restoration of HBV- and HCV-
speciﬁc T-cell reactivity was induced by antiviral treatment.
Therapeutic strategies aimed at correcting defective T-cell
reactivity could represent a complementary approach to the
treatment of chronic viral hepatitis [5, 12–15]. Our data may
provide theoretical foundations for antiviral treatment in
post-hepatitis cirrhosis to some extent. Our study demon-
strated that the impaired immunity in cirrhotic patients is
accompanied by an augmented Treg cell population which
is identical to previous studies [16]. In addition, it has
been recently shown that the decline of circulating Tregs
coincided with a partial recovery of the immune response
during antiviral treatment in chronic hepatitis B. This
indicates that the frequency of circulating Tregs is inversely
correlated with the strength of the immune response and is
associated with viral persistence. Furthermore, in our study,
no diﬀerence of lymphocyte subsets was observed between
the HBV-cirrhotic patients and noncirrhotic hepatitis B4 Journal of Biomedicine and Biotechnology
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Figure 1: Flow cytometry results from a series of representative patients and healthy controls. (a) The cells in the upper left quadrant and
t h el o w e rr i g h to ft h ed o tp l o ta r eC D 3 + CD8+T and CD3+ CD4+T cells, respectively. (b) The cells in the upper left quadrant are NK cells.
(c) The cells in the upper right quadrant of the dot plot are CD4+ CD25+ Foxp3+ Treg.Journal of Biomedicine and Biotechnology 5
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Figure 2: Illustration of lymphocyte subsets in cirrhotic patients and healthy controls. Each symbol represents an individual, and the
medians are shown. (a) CD3+ CD4+T, (b) CD3+ CD8+T, (c) CD4/CD8 ratio, (d) NK, (e) Treg.6 Journal of Biomedicine and Biotechnology
Table 2: T-Lymphocyte cytokine subsets of healthy and cirrhosis patients.
Cytokines (pg/ml) HBV-cirrhosis (n = 42) HCV-cirrhosis (n = 40) Healthy controls (n = 20) P value
IL-2 2.3 (0.5–41.2) 2.3 (0.9–27.3) 2.3 (0.6–10.1) †.4658, ‡.8798
IL-4 2.8 (0.6–37.9) 2.7 (0.7–45.2) 3.0 (1.4–14.9) †.7125, ‡.860
IL-6 11.7 (2.1–100.3) 9.1 (2.1–102.2) 2.5 (1.8–11.9) †<.0001, ‡<.0001
IL-10 2.7 (1.0–39.4) 2.7 (0.5–32.0) 1.6 (1.0–28.4) †.121, ‡.05
TNF-α 2.0 (0.9–22.9) 1.8 (0.8–18.1) 1.6 (0.7–21.8) †.1205, ‡.7624
IFN-γ 7.9 (1.6–84.5) 4.8 (1.2–91.6) 4.4 (1.8–84.5) †.0022, ‡.2787
Data are expressed as median (range); †HBV-cirrhosis versus healthy controls, ‡HCV-cirrhosis versus healthy controls.
patients, which indicated that the diﬀerence in lymphocyte
proportions between cirrhotic patients and healthy controls
was not likely to be due to pancytopenia secondary to
hypersplenism.
An imbalance of Th1 and Th2 may exert a critical
inﬂuence on the inﬂammatory environment and the ﬁnal
outcome of infection [17, 18]. In our observations, cirrhotic
patients showed Th2 proﬁle cytokine secretion dominated
by the production of IL-6, which is in agreement with the
results of Lee et al. [19]. IL-6 is a bidirectional cytokine
with immune-suppressive properties and a hepatoprotective
role [20–22]. In our study, serum IL-6 levels correlated
positively with Child-Pugh scores and TBIL. This implies
that serum IL-6 levels in cirrhosis may reﬂect the degree of
the disease severity and aﬀect the metabolism of bilirubin.
Furthermore, serum IL-6 levels had a negative correlation
with the HBsAg titer which indicates a potential role of IL-
6 in inhibiting and eradicating the virus and viral protein.
The result conﬁrms the ﬁndings of Feldmann et a1. which
showed that a decreased clearance of IL-6 is associated with
cirrhosis [23].
Th1 cytokines are involved in cell-mediated immunity
and play a crucial role in protection from intracellular
pathogens[18].PreviousreportshaveshownthatIFN-γ may
directly inhibit virus replication and mediate liver injury
[24–27]. In our study, serum IFN-γ levels were elevated
in HBV-cirrhosis, but normal in HCV-cirrhosis. Bertoletti
et al. compared liver cytokine proﬁles of hepatitis B and
C demonstrating that the livers of hepatitis B patients had
predominantly Th2 cytokines, while hepatitis C patients had
predominantly Th1 cytokines [18]. Although the number of
patients in our study was small, the diﬀerence in IFN-γ levels
in HBV- and HCV-cirrhosis was likely related to the type of
viral infection rather than to experimental conditions. The
data showed that antiviral immune responses are diﬀerent
in HCV and HBV infections, and these diﬀerences may
have pathogenetic implications. The following three major
interpretations may be drawn. (1) The normal levels of
serum IFN-γ in HCV infection may be due to the IFN-γ
migration to the liver, which was demonstrated indirectly by
Bertoletti et al. [18]. However, we have no data on intra-
hepatic cytokines. (2) IFN-γ c a nb er e g a r d e da sa na t t e m p t
by the immune system to inhibit viral replication and to
eradicate the infection. However, this mechanism would be
insuﬃcient to achieve viral clearance in HCV infection. But,
it could contribute viral persistence, as generally observed
in HCV infection, while the noncytolytic clearance of HBV
requires IFN-γ and TNF-α [27]. (3) The same observation,
however, is also consistent with a threshold phenomenon in
which the loss of IFN-γ production occurs only at or near
the development of HCV-cirrhosis. Our study is consistent
with this hypothesis in that IFN-γ production in HCV-
infected patients with cirrhosis represents a selective defect
in the immune repertoire (possibly induced by HCV itself)
[28]. Therefore, the development of HCV-cirrhosis would
not result primarily from the cytokine, but rather from
other mechanisms or combinations with other cytokines
[18, 24, 25]. With respect to the balance of Th1 and Th2
cytokines, the ratio of IFN-γ to IL-6 in cirrhotic groups was
dramatically lower than that in healthy donors indicating
a shift to a Th2 cytokine proﬁle which diﬀers in many
respects from the study of chronic hepatitis C patients
[24]. The negative eﬀects of post-hepatitis cirrhosis on the
IFN-γ/IL-6 axis strongly support a Th2 predominance in
the peripheral blood of cirrhotic patients indicating an
unfavorable outcome [25, 26].
Our data additionally conﬁrmed previous observations
that HBsAg titers were positively correlated with HBV DNA.
A signiﬁcant reduction in serum HBsAg titer has been
observed with antiviral therapy [29]. Therefore, HBsAg
quantitation may be a surrogate marker for response before,
during, and after antiviral treatment.
In summary, lymphocyte subsets and cytokine pro-
duction were found to display diﬀerent patterns between
cirrhotic patients and healthy donors. The hypothesis of
inadequate innate and adaptive immunity in the cirrhotic
stage can be better tested by performing a longitudinal
study including viral carriers, acutely infected, chronic, and
resolved patients. The present ﬁndings also need to be
conﬁrmed by a study of a larger number of samples and
further follow-up.
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